JAZZ - Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday? | Benzinga
Thursday, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) released topline results from the Phase 2b trial evaluating the efficacy and safety of suvecaltamide (JZP385), an investigational, highly selective and state-dependent modulator of T-type calcium channels, in adult patients with essential tremor (ET).
The Phase 2b study assessed the efficacy and safety of suvecaltamide in a once-daily oral dose of 10, 20, and 30mg or placebo.
Suvecaltamide did not achieve statistical significance at 30mg versus placebo on the primary endpoint ...